Breezula's efficacy story is, on paper, the cleaner one. Two identically designed pivotal Phase 3 trials, SCALP 1 and SCALP 2, together enrolled 1,465 men and both hit statistical significance on the same primary endpoint. There's a real wrinkle worth knowing, the two trials reported very different relative improvement figures (539% and 168%), which Cosmo's CEO has attributed to differing baseline hair counts between the trial populations rather than a difference in drug performance, covered in full in our Breezula article. But both trials were positive, which is the headline that matters for a regulatory filing.

KX-826's efficacy story has been more mixed. An earlier US Phase 2 trial in men reported improvement that didn't reach statistical significance over placebo, a genuinely disappointing result. A China Phase 2 trial in women later showed a statistically significant improvement from baseline at a selected dose. Kintor's actual pivotal male trial is a Phase II/III seamless adaptive design testing 1.0% and 0.5% concentrations; the Phase III stage, which included 666 patients, reportedly met its primary endpoint for both concentrations in March 2026. That's a positive result, but it followed a real miss earlier in development, something Breezula's public trial record doesn't currently include.

On trial scale specifically: Breezula's combined pivotal Phase 3 programme (1,465 patients across two trials) is more than twice the size of KX-826's Phase III stage (666 patients). On consistency and scale of positive results, Breezula currently has the stronger package.

Part of that difference isn't really about which company tried harder, it's a function of which regulator each is targeting. Breezula is heading toward the US FDA and European EMA, where regulatory expectations can favour a more extensive pivotal evidence package, although neither regulator imposes an absolute two-trial rule; FDA generally expects two well-designed trials while explicitly allowing exceptions, and EMA has its own guidance on applications based on a single pivotal Phase 3 study. China's NMPA, which KX-826 is targeting first, can accept a single pivotal Phase 3 study as the principal efficacy study in an application, depending on the overall evidence package, particularly when the trial includes a solid Chinese patient cohort.

Neither approach is wrong. Both reflect the actual requirements of the regulator each company is trying to satisfy first. It does mean a direct trial-count comparison between the two isn't entirely apples to apples.

Cosmo has given specific, current guidance: a US filing targeted for the first quarter of 2027 and an EU filing for the second quarter of 2027, confirmed in the company's July 2026 half-year results. Kintor stated in March 2026 that it plans to communicate with regulators and initiate an NDA submission for KX-826 1.0% in China "in the near term," but hasn't announced a specific target quarter in anything we've located.

China's drug-review system has undergone reforms intended to accelerate review timelines, but that doesn't tell us how quickly a future KX-826 marketing application would actually be reviewed once filed. On specific, confirmed dates, Breezula is currently ahead: it has named quarters for both filings, while KX-826's timetable remains less specific.

Breezula has one real advantage KX-826 doesn't: clascoterone, its active molecule, is already an approved drug in a different form. Winlevi (clascoterone 1% cream) has been used for acne since 2020, giving Cosmo an established human safety base to draw on, albeit at a fifth of Breezula's concentration and applied to different skin. KX-826 has no equivalent approved sibling product anywhere.

Clascoterone already has independently published human pharmacokinetic data from its acne programme: a 2025 peer-reviewed paper covering five Phase 1 studies reported low but measurable systemic exposure with the 1% cream after repeated daily use. A separate Phase 1 study on the compound went further, noting that while the acne cream shows little absorption, the higher-strength solution formulation developed for AGA "leads to a measurable systemic concentration and accumulation" of the drug. KX-826's publicly available PK evidence, by contrast, is still largely company-reported rather than published in an independent, peer-reviewed dataset. Neither dataset, however, is directly comparable to the RU58841 study, the older, unapproved compound in this same mechanism class, covered in our separate article on that finding, in indication, formulation, or study design, so none of the three should be read as a like-for-like safety comparison.

Breezula is aimed first at the US and EU, larger combined markets with regulatory bars that have historically been demanding, particularly the FDA's. KX-826 is aimed first at China, a large market in its own right, under a regulatory system that's been actively reformed in recent years to move faster, though it's still building the kind of decades-long approval track record FDA and EMA have. Neither company has announced firm plans for the other's home market. If either drug is approved, expansion into additional geographies would likely follow as a separate, later process, not something either company has committed to a timeline for yet.

On evidence consistency and trial scale, Breezula: two positive pivotal trials, no reported Phase 3 misses, a larger combined patient count, and an established human safety base from an approved sibling product. On a confirmed, specific regulatory timeline, also Breezula, with named target quarters for both US and EU filings. On which drug might actually reach a regulatory decision first, it's genuinely too early to say: Breezula has the clearer filing timetable, while KX-826's timetable remains less specific.

Neither drug is approved anywhere, and neither is available for purchase through any legitimate channel. If you want a single-word answer to "which is ahead," Breezula currently has the stronger, more consistent public case. The more honest answer is that they're pursuing different regulatory paths at different speeds toward different finish lines, and won't be directly comparable on a single timeline until at least one of them actually reaches a regulatory decision.

This article is provided for educational purposes and does not constitute medical advice. Neither Breezula (clascoterone) nor KX-826 (pyrilutamide) is approved by any regulator or available for purchase through any legitimate channel. AmpleLab products are cosmetic formulations, unrelated to either compound, and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.